BPK Bespak

TIDMCSRT

RNS Number : 8788A

Consort Medical PLC

01 October 2015

Registered Number 406711

Consort Medical plc (the "Company")

Total Voting Rights

The Company hereby notifies the market of the following disclosure with respect to the share capital and voting rights of the Company:

As at the 30 September 2015, the capital of the Company consists of 49,130,358 ordinary shares of 10 pence each with voting rights.

Therefore, the total number of voting rights in the Company is 49,130,358.

Enquiries:

Consort Medical plc

   Iain Ward, Company Secretary                                              01442 867920 

Consort Medical plc is a leading, global, single source drug and delivery device CDMO through its two operating subsidiaries Bespak and Aesica. Consort Medical is at the leading edge of innovation and is committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

The Group has facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, UK; in Monheim and Zwickau, Germany; and in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRUGGGPUUPAURG

(END) Dow Jones Newswires

October 01, 2015 04:23 ET (08:23 GMT)

Bespak (LSE:BPK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Bespak (LSE:BPK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024